Skip to main content
Toggle navigation
Login
Search
Home
Back
Favorite
Locate this booth
Print
Company Details
Contact Info
Sponsored Presentations
(30 items)
Drug Target Review
Drug Target Review
Monday, February 5, 2024
10:00 AM – 12:00 PM
EST
Nucleic Acid-Targeted Therapeutics
Monday, February 5, 2024
10:00 AM – 10:30 AM
EST
Small molecule proximity-induced targeted RNA degraders as research tools and antiviral agents
Monday, February 5, 2024
10:30 AM – 11:00 AM
EST
Oligonucleotide modalities in RNA Therapeutics: the critical steps of target Identification and oligonucleotide design in drug discovery
Monday, February 5, 2024
11:00 AM – 11:30 AM
EST
Expansions of Friedreich's ataxia GAA•TTC repeats: role of DNA replication and prevention by LNA-DNA oligonucleotides
Monday, February 5, 2024
11:30 AM – 12:00 PM
EST
Reprogramming RNA to target unaddressed disease drivers
Monday, February 5, 2024
3:00 PM – 5:00 PM
EST
Induced Proximity Beyond Degradation
Monday, February 5, 2024
3:00 PM – 3:30 PM
EST
Discovery of small molecule molecular glues stabilizing disease-driving proteins to the 14-3-3 adaptor proteins for novel cancer therapeutics
Monday, February 5, 2024
3:30 PM – 4:00 PM
EST
Covalent hit discovery using DNA-encoded library technology
Monday, February 5, 2024
4:00 PM – 4:30 PM
EST
HiBiT cellular thermal shift assays: Learnings from two high-throughput screening campaigns
Monday, February 5, 2024
4:30 PM – 5:00 PM
EST
Reimagining Druggability using Chemoproteomic Platforms
Tuesday, February 6, 2024
10:00 AM – 12:00 PM
EST
Difficult Targets: Expanding Target Space
Tuesday, February 6, 2024
10:00 AM – 10:30 AM
EST
Integrating Artificial Intelligence and Traditional Screens for Targeting “Undruggable" Cancer Targets
Tuesday, February 6, 2024
10:30 AM – 11:00 AM
EST
RAPID – photoaffinity-based high-throughput ligand discovery in cells
Tuesday, February 6, 2024
11:00 AM – 11:30 AM
EST
Targeting ubiquitin protease system to treat MYC-driven breast cancer
Tuesday, February 6, 2024
11:30 AM – 12:00 PM
EST
Sorafenib and Lenvatinib induce vascular responses in patient derived HCC on-Chip models
Tuesday, February 6, 2024
3:00 PM – 5:00 PM
EST
Next Generation Protein Therapeutics
Tuesday, February 6, 2024
3:00 PM – 3:30 PM
EST
Engineering cytokine/antibody fusion proteins as targeted immunotherapeutics
Tuesday, February 6, 2024
3:30 PM – 4:00 PM
EST
Engineering High Avidity, Low Affinity (HALA) Antibodies to Auto-Tune the Delivery of Antibody Drug Conjugates In Vivo
Tuesday, February 6, 2024
4:00 PM – 4:30 PM
EST
Continuous Protein Evolution Enabled by Machine Learning and Laboratory Automation
Tuesday, February 6, 2024
4:30 PM – 5:00 PM
EST
Orchestrated Laboratory Robotics: Development of 3rd Generation Robotics for Biologics Development
Wednesday, February 7, 2024
9:30 AM – 11:30 AM
EST
Biomolecular Condensates
Wednesday, February 7, 2024
9:30 AM – 10:00 AM
EST
Leveraging automation and AI for high-throughput discovery of condensate-modifying drugs
Wednesday, February 7, 2024
10:00 AM – 10:30 AM
EST
Novel Phase Separation Modifying therapeutics target Biomolecular interactions to unlock difficult- to-drug proteins
Wednesday, February 7, 2024
10:30 AM – 11:00 AM
EST
Identification of Small Molecule Inhibitors of hyperphosphorylated tau (p-tau) Aggregation Via High Throughput Screening
Wednesday, February 7, 2024
11:00 AM – 11:30 AM
EST
Screen for Modulation of Nucleocapsid Protein Condensation Identifies Small Molecules with Anti-Coronavirus Activity
Wednesday, February 7, 2024
12:30 PM – 2:30 PM
EST
Emerging Drug Discovery Technologies
Wednesday, February 7, 2024
12:30 PM – 1:00 PM
EST
Advancing the science of Radiopharmaceutical Therapy : a renewed hope for new cancer treatments
Wednesday, February 7, 2024
1:00 PM – 1:30 PM
EST
Alpha Emitters — Decay Chains, Chelation Chemistry & Radiopharmaceuticals — An Overview
Wednesday, February 7, 2024
1:30 PM – 2:00 PM
EST
Rapid optimization of small molecules using a fusion of physics-based simulations, AI and parallel chemistry
Wednesday, February 7, 2024
2:00 PM – 2:30 PM
EST
Radiotheranostic development from lab to clinic – challenges and opportunities.
.png)
